We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The synergistic mechanisms of propofol with cisplatin or doxorubicin in human ovarian cancer cells.
- Authors
Sue, Sung-How; Tseng, Wei-Cheng; Wu, Zih-Syuan; Huang, Shih-Ming; Chen, Jia-Lin; Wu, Zhi-Fu; Lai, Hou-Chuan
- Abstract
Background: Most ovarian cancer cases are diagnosed at an advanced stage, leading to poor outcomes and a relatively low 5-year survival rate. While tumor resection in the early stages can be highly effective, recurrence following primary treatment remains a significant cause of mortality. Propofol is a commonly used intravenous anesthetic agent in cancer resection surgery. Previous research has shown that propofol anesthesia was associated with improved survival in patients undergoing elective surgery for epithelial ovarian cancer. However, the underlying antitumor mechanisms are not yet fully understood. Methods: This study aimed to uncover the antitumor properties of propofol alone and combined with cisplatin or doxorubicin, in human SKOV3 and OVCAR3 ovarian cancer cells. We applied flowcytometry analysis for mitochondrial membrane potential, apoptosis, and autophagy, colony formation, migration, and western blotting analysis. Results: Given that chemotherapy is a primary clinical approach for managing advanced and recurrent ovarian cancer, it is essential to address the limitations of current chemotherapy, particularly in the use of cisplatin and doxorubicin, which are often constrained by their side effects and the development of resistance. First of all, propofol acted synergistically with cisplatin and doxorubicin in SKOV3 cells. Moreover, our data further showed that propofol suppressed colony formation, disrupted mitochondrial membrane potential, and induced apoptosis and autophagy in SKOV3 and OVCAR3 cells. Finally, the effects of combined propofol with cisplatin or doxorubicin on mitochondrial membrane potential, apoptosis, autophagy, and epithelial-mesenchymal transition were different in SKOV3 and OVCAR3 cells, depending on the p53 status. Conclusion: In summary, repurposing propofol could provide novel insights into the existing chemotherapy strategies for ovarian cancer. It holds promise for overcoming resistance to cisplatin or doxorubicin and may potentially reduce the required chemotherapy dosages and associated side effects, thus improving treatment outcomes.
- Subjects
OVARIAN epithelial cancer; MEMBRANE potential; MITOCHONDRIAL membranes; WESTERN immunoblotting; CISPLATIN; INTRAVENOUS anesthetics
- Publication
Journal of Ovarian Research, 2024, Vol 17, Issue 1, p1
- ISSN
1757-2215
- Publication type
Article
- DOI
10.1186/s13048-024-01509-x